Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Neumora Therapeutics Inc. shares valued at $124,603 were purchased by Lenz Robert A. on Oct 10 ’24. At $15.09 per share, Lenz Robert A. acquired 8,260 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Lenz Robert A. purchased 5,563 shares, netting a total of over 83,507 in proceeds.
Before that, Lenz Robert A. had sold 30,788 shares from its account. In a trade valued at $363,736, the Head of R&D traded Neumora Therapeutics Inc. shares for $11.81 each. Upon closing the transaction, the insider’s holdings decreased to 30,788 shares, worth approximately $5.22 million.
As published in their initiating research note from H.C. Wainwright on October 01, 2024, Neumora Therapeutics Inc. [NMRA] has been a Buy and the price target has been revised to $30. Analysts at Needham started covering the stock with ‘”a Buy”‘ outlook in a report released in late July. As of July 08, 2024, Mizuho has initiated its “an Outperform” rating for NMRA. Earlier on December 12, 2023, Deutsche Bank initiated its rating. Their recommendation was “a Hold” for NMRA stock.
Analyzing NMRA Stock Performance
During the last five days, there has been a surge of approximately 13.70%. Over the course of the year, Neumora Therapeutics Inc. shares have dropped approximately -9.68%. Shares of the company reached a 52-week high of $21.00 on 03/08/24 and a 52-week low of $8.33 on 06/26/24. A 50-day SMA is recorded $12.22, while a 200-day SMA reached $12.84. Nevertheless, trading volume fell to 1.51 million shares from 0.94 million shares the previous day.
Support And Resistance Levels for Neumora Therapeutics Inc. (NMRA)
According to the 24-hour chart, there is a support level at 14.10, which, if violated, would cause prices to drop to 12.80. In the upper region, resistance lies at 16.35. The next price resistance is at 17.30. RSI (Relative Strength Index) is 70.79 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.11, which suggests the price will increase in the coming days. Percent R is at 15.00%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
